Question Everything. See who's reporting it.

Kerala HC orders government to tackle exorbitant pricing of breast cancer drugs

Source: Indian Express

The story in brief

The Kerala High Court ruled that the government must address exorbitant pricing of abemaciclib and ribociclib, which target CDK4/6 proteins in breast cancer. Despite generating $19.6 billion and $12.7 billion in sales, the medicines remain patented, limiting generic competition. Patients may not see immediate relief as the government lacks a timeline or clear responsibility.

NEWXFree on Android and iPhone. Open in NEWX